Feb 7 (Reuters) - Sage Therapeutics Inc:
* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL-TOLERATED
* SAGE THERAPEUTICS INC - IN TRIAL, SAGE-217 MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage: